Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston’s heart stent gets European clearance for new uses
In addition to its existing indication for the treatment of de-novo lesions in native coronary arteries, the Taxus liberte stent system is now indicated in Europe for the
In addition to its existing indication for the treatment of de-novo lesions in native coronary arteries, the Taxus liberte stent system is now indicated in Europe for the
The FDA informed the company that it will most probably require a dose-ranging study on subcutaneously administered DX-88 in order to support the company's application for approval. Dyax,
The selection of NCX 1047 marks the successful completion of the partners' research program to identify a new synthetic nitric oxide (NO)-donating corticosteroid with the potential for an
Bioenvision will receive milestone payments and a percentage of Mayne's net sales revenue. Mayne Pharma is responsible for securing regulatory approval and government reimbursement in Australia and New
Analysis of data from the trial indicates that, so far, 21% of patients in the trial have achieved either a clinical response to treatment or stabilization of their
The study was designed to evaluate the protective effect of MU1140 when administered by intravenous injection to mice infected intraperitoneally with a lethal dose of Staphylococcus aureus. The
The designation provides Oxigene with several potential benefits for combretastatin A4P (CA4P), including a guarantee of seven years of market exclusivity upon approval in the ovarian cancer indication.
The trial examines the safety and potential efficacy for pixantrone when substituted for mitoxantrone in the established FND-R chemotherapy regimen for non-Hodgkin's lymphoma (NHL) patients who had failed
The proposals, which were passed on a second vote in the EU parliament, will require specific thresholds for claims such as 'low fat', 'high fiber' or 'reduced sugar'.
Roche will provide technical know-how to assist Aspen in the production and registration of the generic product, and also supply the active pharmaceutical ingredient to the African company.